newsfilter
← Latest News
Business Wire·

Savara to Present New Analysis from the IMPALA Clinical Trial and Deliver Encore Presentation of Long-Term Data on Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at CHEST 2026

-- Company to Host Learning Theatre on aPAP with Renowned Key Opinion Leader Along with Members of the Patient Community -- Savara Inc. (NASDAQ:SVRA), a clinical-stage biopharmaceutical company focused on rare